Design Therapeutics Inc
NASDAQ:DSGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Design Therapeutics Inc
NASDAQ:DSGN
|
US |
|
M
|
Mitsubishi Electric Corp
OTC:MIELF
|
JP |
|
J
|
JD.Com Inc
NASDAQ:JD
|
CN |
|
V
|
Vontobel Holding AG
OTC:VONHF
|
CH |
|
C
|
China Tianrui Group Cement Co Ltd
F:T18
|
CN |
|
Ashiana Housing Ltd
NSE:ASHIANA
|
IN |
|
B
|
BAE Systems PLC
XETRA:BSP
|
UK |
|
M
|
Medbright AI Investments Inc
CNSX:MBAI
|
CA |
|
N
|
Natural Resource Holdings Inc
OTC:NRHI
|
US |
|
G
|
Gaon Group Ltd
TASE:GAGR
|
IL |
|
I
|
Izoblok SA
WSE:IZB
|
PL |
|
Hanchang Corp
KRX:005110
|
KR |
|
Matriks Bilgi Dagitim Hizmetleri AS
IST:MTRKS.E
|
TR |
|
Z
|
Zur Rose Group AG
SIX:ROSE
|
CH |
|
Z
|
Zhejiang Daily Digital Culture Group Co Ltd
SSE:600633
|
CN |
|
Signpost Corp
TSE:3996
|
JP |
|
R
|
Ralph Lauren Corp
LSE:0KTS
|
US |
|
Wuling Motors Holdings Ltd
HKEX:305
|
HK |
|
V
|
Versatile Creative Bhd
KLSE:VERSATL
|
MY |
|
C
|
China Everbright Ltd
HKEX:165
|
HK |
|
Key Coffee Inc
TSE:2594
|
JP |
|
S
|
Showbox Corp
KOSDAQ:086980
|
KR |
|
Episurf Medical AB
STO:EPIS B
|
SE |
|
Cogent Communications Holdings Inc
NASDAQ:CCOI
|
US |
Design Therapeutics Inc
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 37 full-time employees. The company went IPO on 2021-03-26. The firm is focused on gene-targeted chimeras (GeneTAC) molecules, which is a class of small-molecule gene-targeted chimera therapeutic candidates that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The firm's lead product candidate is Friedreich ataxia (FA). The firm is also developing the GeneTAC program in myotonic dystrophy type-1 (DM1), and it is advancing its GeneTAC portfolio to address other serious nucleotides repeat-driven monogenic diseases. Its FA is a monogenic, autosomal recessive progressive disease. Its DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain and other organs.
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 37 full-time employees. The company went IPO on 2021-03-26. The firm is focused on gene-targeted chimeras (GeneTAC) molecules, which is a class of small-molecule gene-targeted chimera therapeutic candidates that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The firm's lead product candidate is Friedreich ataxia (FA). The firm is also developing the GeneTAC program in myotonic dystrophy type-1 (DM1), and it is advancing its GeneTAC portfolio to address other serious nucleotides repeat-driven monogenic diseases. Its FA is a monogenic, autosomal recessive progressive disease. Its DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain and other organs.
